Orthovita, a specialty spine and orthopedic company, has announced fourth quarter 2010 product sales of $23.4 million, representing a 4 percent decrease from 4Q 2009, according to a company news release.
The decline in revenue can be attributed to decreased sales of the Vitoss Synthetic Bone Graft Substitute products, which declined 6 percent in 4Q 2010 compared to 4Q 2009. Although sales of Vitoss Bioactive Foam products and Vitoss Morsels increased 3 percent and 1 percent, respectively, these increases were offset by a significant decrease in sales of Vitoss Foam products.
Read the company news release about Orthovita's 4Q financial results (pdf).
Read other coverage about device companies' financial results:
- MAKO Surgical Posts 4Q Revenue of $14.8M, 67% Increase
- Exactech Announces 4Q Revenue of $51.8M, 7% Increase
- TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease
The decline in revenue can be attributed to decreased sales of the Vitoss Synthetic Bone Graft Substitute products, which declined 6 percent in 4Q 2010 compared to 4Q 2009. Although sales of Vitoss Bioactive Foam products and Vitoss Morsels increased 3 percent and 1 percent, respectively, these increases were offset by a significant decrease in sales of Vitoss Foam products.
Read the company news release about Orthovita's 4Q financial results (pdf).
Read other coverage about device companies' financial results:
- MAKO Surgical Posts 4Q Revenue of $14.8M, 67% Increase
- Exactech Announces 4Q Revenue of $51.8M, 7% Increase
- TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease